BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.30−0.20 (-2.67%)
Close on Nov 18, 2026Market cap $1.87BP/E –Yield –
BioCryst Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BioCryst Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $940.61M, up 68.7% year over year. For fiscal 2025 it was $874.84M, up 94.1% from the year before. Over ten years it grew 33.6% a year on average. The highest annual figure on record is $874.84M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $874.84M | +94.1% |
| FY2024 | Dec 31, 2024 | $450.71M | +36.0% |
| FY2023 | Dec 31, 2023 | $331.41M | +22.4% |
| FY2022 | Dec 31, 2022 | $270.83M | +72.3% |
| FY2021 | Dec 31, 2021 | $157.17M | +782.4% |
| FY2020 | Dec 31, 2020 | $17.81M | -63.5% |
| FY2019 | Dec 31, 2019 | $48.84M | +136.5% |
| FY2018 | Dec 31, 2018 | $20.65M | -18.0% |
| FY2017 | Dec 31, 2017 | $25.19M | -4.4% |
| FY2016 | Dec 31, 2016 | $26.35M | -45.4% |
| FY2015 | Dec 31, 2015 | $48.26M | +254.6% |
| FY2014 | Dec 31, 2014 | $13.61M | -21.5% |
| FY2013 | Dec 31, 2013 | $17.33M | -34.1% |
| FY2012 | Dec 31, 2012 | $26.29M | +33.9% |
| FY2011 | Dec 31, 2011 | $19.64M | -68.5% |
| FY2010 | Dec 31, 2010 | $62.38M | -16.4% |
| FY2009 | Dec 31, 2009 | $74.59M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $218.25M | +33.6% |
| Q1 FY2026 | Mar 31, 2026 | $156.41M | +7.5% |
| Q4 FY2025 | Dec 31, 2025 | $406.56M | +209.1% |
| Q3 FY2025 | Sep 30, 2025 | $159.40M | +36.1% |
| Q2 FY2025 | Jun 30, 2025 | $163.35M | +49.4% |
| Q1 FY2025 | Mar 31, 2025 | $145.53M | +56.9% |
| Q4 FY2024 | Dec 31, 2024 | $131.53M | +40.8% |
| Q3 FY2024 | Sep 30, 2024 | $117.09M | +35.0% |
| Q2 FY2024 | Jun 30, 2024 | $109.33M | +32.5% |
| Q1 FY2024 | Mar 31, 2024 | $92.76M | +34.9% |
| Q4 FY2023 | Dec 31, 2023 | $93.40M | +17.4% |
| Q3 FY2023 | Sep 30, 2023 | $86.74M | +14.4% |
| Q2 FY2023 | Jun 30, 2023 | $82.49M | +25.9% |
| Q1 FY2023 | Mar 31, 2023 | $68.78M | +37.8% |
| Q4 FY2022 | Dec 31, 2022 | $79.55M | +68.7% |
| Q3 FY2022 | Sep 30, 2022 | $75.83M | +85.0% |
| Q2 FY2022 | Jun 30, 2022 | $65.53M | +31.2% |
| Q1 FY2022 | Mar 31, 2022 | $49.92M | +161.9% |
| Q4 FY2021 | Dec 31, 2021 | $47.16M | +1074.3% |
| Q3 FY2021 | Sep 30, 2021 | $40.99M | +571.8% |
| Q2 FY2021 | Jun 30, 2021 | $49.96M | +1640.1% |
| Q1 FY2021 | Mar 31, 2021 | $19.06M | +295.2% |
| Q4 FY2020 | Dec 31, 2020 | $4.02M | -89.9% |
| Q3 FY2020 | Sep 30, 2020 | $6.10M | +243.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.87M | +98.3% |
| Q1 FY2020 | Mar 31, 2020 | $4.82M | -18.1% |
| Q4 FY2019 | Dec 31, 2019 | $39.73M | +1355.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.78M | +22.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.45M | -88.4% |
| Q1 FY2019 | Mar 31, 2019 | $5.89M | +48.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.73M | -29.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.45M | -83.4% |
| Q2 FY2018 | Jun 30, 2018 | $12.49M | +303.2% |
| Q1 FY2018 | Mar 31, 2018 | $3.98M | -57.9% |
| Q4 FY2017 | Dec 31, 2017 | $3.89M | -56.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.76M | +12.8% |
| Q2 FY2017 | Jun 30, 2017 | $3.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.98M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.76M | – |
See a number that looks wrong?